Shares of Ascendis Pharma (ASND) are down $5.82, or 4%, to $155.33 in morning trading in New York. The move lower began near the open and may be related to the start of today’s Committee for Medicinal Products for Human Use meeting being held by the European Medicines Agency at 10 am New York time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Reddit initiated, Target downgraded: Wall Street’s top analyst calls
- Ascendis Pharma initiated with an Outperform at RBC Capital
- Strong Initial Demand and Encouraging Payor Coverage Drive Buy Rating for Ascendis Pharma’s Yorvipath
- Ascendis Pharma Grants Employee Warrants to Boost Retention
- Buy Rating for Ascendis Pharma Driven by Promising TransCon CNP Developments and Strong Growth Prospects